Publications by authors named "R A OLIVERI"
Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study.
J Immunother Cancer
January 2025
Background: Second-line treatment options for persistent, recurrent or metastatic (r/m) cervical cancer are limited. We investigated the safety, efficacy, and immunogenicity of the therapeutic DNA-based vaccine VB10.16 combined with the immune checkpoint inhibitor atezolizumab in patients with human papillomavirus (HPV)16-positive r/m cervical cancer.
View Article and Find Full Text PDFDespite the worldwide recommendations for influenza immunisation, vaccination coverage for patients exposed to the highest risk of severe complications is still far from the optimal target. The need to take advantage of alternative methods to provide vaccination is essential. This study presents a hospital-based strategy which offers influenza vaccination to inpatients at discharge.
View Article and Find Full Text PDFIn this Letter, we present the design and performance of the frequency-dependent squeezed vacuum source that will be used for the broadband quantum noise reduction of the Advanced Virgo Plus gravitational-wave detector in the upcoming observation run. The frequency-dependent squeezed field is generated by a phase rotation of a frequency-independent squeezed state through a 285 m long, high-finesse, near-detuned optical resonator. With about 8.
View Article and Find Full Text PDFBackground: This study evaluated the clinical outcomes of patients with severe COVID-19 pneumonia treated with remdesivir plus standard corticosteroid treatment (SCT) or with remdesivir plus high-dose corticosteroid pulse therapy (HDCPT).
Methods: One hundred and two patients with severe COVID-19 pneumonia and respiratory failure were included. The patients were divided into two cohorts.
Article Synopsis
- Epcoritamab is a bispecific antibody targeting CD3 and CD20, designed to activate T cells to kill cancerous B cells and is currently in a phase I/II clinical trial to find the safest and most effective dose.
- The trial involves a unique pharmacokinetic/pharmacodynamic model to better predict how the drug interacts with the body and how it influences tumor response, rather than using traditional modeling methods which may not be sufficient.
- Results indicate that a dose of 48 mg optimally triggers T cell responses in conditions like diffuse large B-cell lymphoma and follicular lymphoma without significantly increasing the risk of cytokine release syndrome.